Abstract
Bisphosphonates are the current standard of care for patients with bone metastases from advanced solid tumors. Zoledronic acid has demonstrated the broadest activity in this setting, and is approved for the prevention of skeletal-related events from bone metastases from a variety of solid tumors in addition to breast cancer and multiple myeloma. Ongoing studies are evaluating the antiresorptive potentials of investigational agents in these settings. A large body of preclinical evidence and recent clinical developments support the hypothesis that zoledronic acid can exert clinically meaningful anticancer activities in some settings, thereby improving disease outcomes and survival. These data are especially strong in breast cancer and multiple myeloma, and are emerging in other cancer settings. This review article will discuss the emerging data suggesting an anticancer role for bisphosphonates in the context of lung cancer and solid tumors other than breast and genitourinary malignancies.
Keywords: Bone metastases, Non-small cell lung cancer, Skeletal-related events, Zoledronic acid, Bone markers, Survival, Skeletal Morbidity, NTX levels, ZOL infusion
Anti-Cancer Agents in Medicinal Chemistry
Title: Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?
Volume: 12 Issue: 2
Author(s): Vera Hirsh
Affiliation:
Keywords: Bone metastases, Non-small cell lung cancer, Skeletal-related events, Zoledronic acid, Bone markers, Survival, Skeletal Morbidity, NTX levels, ZOL infusion
Abstract: Bisphosphonates are the current standard of care for patients with bone metastases from advanced solid tumors. Zoledronic acid has demonstrated the broadest activity in this setting, and is approved for the prevention of skeletal-related events from bone metastases from a variety of solid tumors in addition to breast cancer and multiple myeloma. Ongoing studies are evaluating the antiresorptive potentials of investigational agents in these settings. A large body of preclinical evidence and recent clinical developments support the hypothesis that zoledronic acid can exert clinically meaningful anticancer activities in some settings, thereby improving disease outcomes and survival. These data are especially strong in breast cancer and multiple myeloma, and are emerging in other cancer settings. This review article will discuss the emerging data suggesting an anticancer role for bisphosphonates in the context of lung cancer and solid tumors other than breast and genitourinary malignancies.
Export Options
About this article
Cite this article as:
Hirsh Vera, Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (2) . https://dx.doi.org/10.2174/187152012799014922
DOI https://dx.doi.org/10.2174/187152012799014922 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Spectrum of Multimodality Findings in Post-surgical Breast Cancer Imaging
Current Medical Imaging Nanoparticles, Promising Carriers in Drug Targeting: A Review
Current Drug Therapy Cinnamic Acid Derivatives Induce Cell Cycle Arrest in Carcinoma Cell Lines
Medicinal Chemistry Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Intramammary Application of Non-Methylated-CpG Oligodeoxynucleotides (CpG) Inhibits both Local and Systemic Mammary Carcinogenesis in Female BALB/c Her-2/neu Transgenic Mice
Current Cancer Drug Targets Anti-cancer Scopes and Associated Mechanisms of Scutellaria Extract and Flavonoid Wogonin
Current Cancer Therapy Reviews Biomedical Applications of Gold Nanoparticles
Current Topics in Medicinal Chemistry Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Nanoparticles in Melanoma
Current Medicinal Chemistry MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Current Pharmaceutical Design Intracellular Expression of Inflammatory Proteins S100A8 and S100A9 Leads to Epithelial-mesenchymal Transition and Attenuated Aggressivity of Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Methotrexate: Should We Start Using it in Clinical Practice?
Current Drug Targets From Bacteria to Antineoplastic: Epothilones A Successful History
Anti-Cancer Agents in Medicinal Chemistry Targeting the Cancer Biomarker CD47: A Review on the Diverse Mechanisms of the CD47 Pathway in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?
Current Hypertension Reviews New N,C-Diaryl-1,2,4-triazol-3-ones: Synthesis and Evaluation as Anticancer Agents
Medicinal Chemistry Tuftsin – Properties and Analogs
Current Medicinal Chemistry Berberine Administration in Treatment of Colitis: A Review
Current Drug Targets Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets